UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RDID00112CIPUS

Total Pages in this Submission 115

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Tran	Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an									
inver	invention entitled:									
D	NEW FORMS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE DEHYDROGENASE									
and i	nvent	ed by	<i>'</i> :							- 200 = 62
K	KNAPPE, Wolfgang-Reinhold									
If a (CONT	INU	ATION	I AP	PLICATION,	chec	k appropriate b	ox and supply	the requisite information:	
	Cont	inua	tion		Divisional	X	Continuation-	in-part (CIP)	of prior application No.:	09/710,197
Whic	ch is a	a:							-	
	Cont	inua	tion		Divisional		Continuation-	in-part (CIP)	of prior application No.:	
Whic	ch is a	1 :							-	
	Cont		ion		Divisional		Continuation-	in-part (CIP)	of prior application No.:	
	osed a								-	
Encl	osed	are:								
							Application	n Elements		
, 1.	1. Filing fee as calculated and transmitted as described below									
			_							
2.	. 🛛	Spe	cifica	tion ł	naving		34	_ pages and in	cluding the following:	
	a. ⊠ Descriptive Title of the Invention									
	b. 🗵 Cross References to Related Applications (if applicable)									
	c. Statement Regarding Federally-sponsored Research/Development (if applicable)									
	d. Reference to Microfiche Appendix (if applicable)									
	e. 🗵 Background of the Invention									
	f.	\boxtimes			nmary of the					
	g.	_ ⊠					wings <i>(if drawin</i>	an filed)		
	h.				Description	Dia	wiigs (ii urawiii	gs meu)		
		<u> </u>			as Classified	Dolo				
							VV			
	J.	X	Abst	act o	of the Disclos	ure				

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RDID00112CIPUS

Total Pages in this Submission 115

					Application Elements (Continued)					
	3.	X	Dra	awing(s) (when $n\epsilon$	ecessary as prescribed by 35 USC 113)					
		a.	X	Formal	Number of Sheets7					
		b.		Informal	Number of Sheets					
	4.	×	Oath or Declaration							
		a.		Newly executed	(original or copy) 🗵 Unexecuted					
9 . A		b.		Copy from a prid	or application (37 CFR 1.63(d)) (for continuation/divisional application only)					
i a		C.	\boxtimes	With Power of A	Attorney Without Power of Attorney					
And the party an		d.		DELETION OF Signed statements see 37 C.F.R. 1	INVENTOR(S) nt attached deleting inventor(s) named in the prior application, .63(d)(2) and 1.33(b).					
Action of the latest desired from the latest through the	5.		The Box	e entire disclosure	erence (usable if Box 4b is checked) e of the prior application, from which a copy of the oath or declaration is supplied under ed as being part of the disclosure of the accompanying application and is hereby rence therein.					
22 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	6.		Con	nputer Program ir	n Microfiche (Appendix)					
# 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	7.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)							
		a.	☑ Paper Copy							
Per.		b.	\boxtimes	Computer Read	able Copy (identical to computer copy)					
		C.	\boxtimes	Statement Verify	ying Identical Paper and Computer Readable Copy					
			Accompanying Application Parts							
	8.		Assi	ignment Papers (cover sheet & document(s))					
9.			37 CFR 3.73(B) Statement (when there is an assignee)							
1	10.		English Translation Document (if applicable)							
11.			Information Disclosure Statement/PTO-1449 Copies of IDS Citations							
1	12.			liminary Amendmo						
1	13.	\boxtimes	Ackr	nowledgment pos	tcard					
1	14.	X	Cert	tificate of Mailing						
				First Class	Express Mail (Specify Label No.): EL566320370US					

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
RDID00112CIPUS

Total Pages in this Submission 115

Accompanying Application Parts (Continued)

15.	\boxtimes	Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	×	Additional Enclosures (please identify below):
		General Appointment of Representative for U.S. Patent and Trademark Office Matters.

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RDID00112CIPUS

Total Pages in this Submission 115

Indep. Claims 8 - 3 = 5 x \$84.00 \$420.0 Multiple Dependent Claims (check if applicable) BASIC FEE \$740.0 OTHER FEE (specify purpose) \$0.0	Fee Calculation and Transmittal						
Total Claims 30 -20 = 10 x \$18.00 \$180.0 \$420.0 Multiple Dependent Claims (check if applicable) BASIC FEE \$740.0 TOTAL FILING FEE \$1,340.0 A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,			CLAIMS	AS FILED		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
### A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,	For	#Filed	#Allowed	#Extra		Rate	Fee
Multiple Dependent Claims (check if applicable) BASIC FEE \$740.0 TOTAL FILING FEE \$1,340.0 A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,	Total Claims	30	- 20 =	10	x	\$18.00	\$180.00
BASIC FEE \$740.0 OTHER FEE (specify purpose) \$0.0 TOTAL FILING FEE \$1,340.0 A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,	ndep. Claims	8	- 3 =	5	x	\$84.00	\$420.00
OTHER FEE (specify purpose) TOTAL FILING FEE \$1,340.0 A check in the amount of to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,		aims (check if	applicable)				\$0.00
TOTAL FILING FEE \$1,340.0 ☐ A check in the amount of to cover the filing fee is enclosed. ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. ☐ Charge the amount of as filing fee. ☐ Credit any overpayment. ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,						BASIC FEE	\$740.00
 □ A check in the amount of to cover the filing fee is enclosed. ☑ The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. ☑ Charge the amount of as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, 	OTHER FEE (specify	purpose)					\$0.00
The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed. ☐ Charge the amount of as filing fee. ☐ Credit any overpayment. ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,						TOTAL FILING FEE	\$1,340.00
Signature Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation							

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kratzsch et al.

Application No.: Unknown

Group No.: Unknown

Filed: October 29, 2001

Examiner: Unknown

For: NEW FORMS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE

DEHYDROGENASE

Box SN Assistant Commissioner for Patents Washington, D.C. 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Dear Sir:

The undersigned hereby states that the content of the Sequence Listing filed herewith (13 pages, numbered 1 to 13) and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same and contain no new matter. Also enclosed is a Checker 3.0 Verification Summary Report demonstrating that the Sequence Listing complies with the applicable rules.

Date: <u>October 29, 2001</u>

Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation 9115 Hague Road, Bldg. D

P.O. Box 50457

Indianapolis, IN 46250-0457 Telephone: (317) 521-3104

Respectfully submitted.

<u></u>									
CERTIFICATE OF	MAILING BY "EXPRESS I	MAIL" (37 CFR 1.10)	Docket No.						
Applicant(s): KRATZSCH, Peter, et al. RDID00112CIPUS									
			RDD00112CH US						
Serial No. Filing Date Examiner Group Art Unit									
The Property of the Control of the C									
To Be Assigned October 29, 2001 To Be Assigned To Be Assigned									
Invention: NEW FORMS OF SOLUBLE PYRROLOQUINOLINE QUINONE-DEPENDENT GLUCOSE									
DEHYDROGENASE									
DEHIDROGENASE									
I hereby certify that this	e II C	CID TIGHT DATE A SERVICE							
Thoroby certify that this		CIP Utility Patent Application (Identify type of correspondence)							
ind.									
is being deposited with	the United States Postal Service	ce "Express Mail Post Office to A	Addrosoo all comico conde						
	Tario Office Otales Fostar Octor	Ze Express Mail Fost Office to A	Addressee Service under						
37 CFR 1.10 in an env	elope addressed to: The Assista	nt Commissioner for Patents, Wa	ashington D.C. 20231 on						
October 2	9, 2001.	The Commission of Fatorito, VVC	351111gtori, B.O. 2023 F 011						
October 2 (Date)									
2. A.									
°F ≅		Rose Edward							
		(Typed or Printed Name of Person Mai	ling Correspondence)						
		Rose Edu	m/dn						
The state of the s		(Signature of Person Mailing Co	orrespondence)						
The state of the s			• /						
		EL5663203701	US						
and the second s	("Express Mail" Mailing Label Number)								
· ·									
Note: Each paper must have its own certificate of mailing.									
		<u> </u>							